Skip to main content

Fecal Microbiota Transplantation Aids Resolution of Recurrent C. Difficile

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

TUESDAY, May 16, 2023 -- For immunocompetent adults with recurrent Clostridioides difficile infection (rCDI), fecal microbiota transplantation (FMT) yields a significant increase in resolution compared with alternative treatments, according to a review published online April 25 in the Cochrane Library.

Nathan Zev Minkoff, M.D., from Valley Children's Hospital in Madera, California, and colleagues examined the benefits and harms of donor-based FMT for treatment of rCDI in immunocompetent adults versus placebo, autologous FMT, no intervention, or antibiotics. Data were pooled from six studies with 320 adult participants.

The researchers found that use of FMT in immunocompetent participants with rCDI likely leads to a large increase in resolution of rCDI compared with control (risk ratio, 1.92; 95 percent confidence interval, 1.36 to 2.71; P = 0.02). FMT probably yields a slight reduction in serious adverse events, but the investigators did not find a significant association (risk ratio, 0.73; 95 percent confidence interval, 0.38 to 1.41; P = 0.24). FMT may reduce the risk for all-cause mortality, but the number of events was small and confidence intervals were wide (risk ratio, 0.57; 95 percent confidence interval, 0.22 to 1.45; P = 0.48).

"The risk of recurrence increases to about 40 percent with the second episode and to nearly 60 percent with the third episode. So, once you are in this cycle, it gets more and more difficult to break out of it," a coauthor said in a statement. "Stool transplants can reverse the dysbiosis and thus decrease the risk of recurrence of the disease."

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted May 2023

Read this next

Reduced Vancomycin Susceptibility Tied to Poorer C. Diff Outcomes

TUESDAY, April 30, 2024 -- Reduced vancomycin susceptibility is impacting clinical responses among adults with Clostridioides difficile (C. difficile) infection, according to a...

AGA Recommends Fecal Microbiota Transplant for Recurrent C. Difficile

MONDAY, Feb. 26, 2024 -- Fecal microbiota transplant is recommended on completion of standard-of-care antibiotics to prevent recurrence for adults with recurrent Clostridioides...

Ingestion Hazard Prompts Recall of Small Magnetic Balls

FRIDAY, Dec. 29, 2023 -- Citing thousands of hospitalizations and at least seven deaths linked to high-powered magnetic balls, the U.S. Consumer Product Safety Commission...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.